Jun.07 -- The FDA approved Biogen's controversial Alzheimer’s disease therapy, which will be sold under the name Aduhelm. The drug works by removing amyloid, a harmful protein that clogs the brains of Alzheimer’s patients. Bloomberg's Drew Armstrong reports on "Bloomberg Markets: European Close."